<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099162</url>
  </required_header>
  <id_info>
    <org_study_id>4-2008-0030</org_study_id>
    <nct_id>NCT02099162</nct_id>
  </id_info>
  <brief_title>Yonsei OCT (Optical Coherence Tomography) Registry for Evaluation of Efficacy and Safety of Coronary Stenting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optical coherence tomography (OCT) has been recently studied for evaluation of coronary
      stenting. Because of high resolutions, several reports have shown that OCT is appropriate for
      evaluating neointimal tissue after coronary stent implantation. Also, the strut coverage and
      the characterization of neointimal tissue can be accurately evaluated. Furthermore,
      OCT-defined coverage of a stent strut was proposed to be related with clinical safety in
      drug-eluting stents-treated patients. Therefore, the investigators will evaluate the
      appropriateness of currently using coronary stents (e.g. Sirolimus eluting stent,
      Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus
      eluting stent, EPC(endothelial progenitor cell) Capture stent, etc) based on the findings of
      OCT. Additionally, the investigators will evaluate neointimal hyperplasia, malposition or
      strut coverage to decide the differences in the stent characteristics, the duration of
      antiplatelet use, and the differences according to the clinical presentations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2007</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OCT findings (stented lesions, native vessels)</measure>
    <time_frame>at index PCI, at follow-up coronary angiography (3, 6, 9 or 12 months and at the time clinically indicated)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Death, Cardiac death, Stent thrombosis, Myocardial infarction, Target-lesion revascularization, Target-vessel revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of OCT findings with physiologic findings</measure>
    <time_frame>at index PCI, at follow-up coronary angiography (3, 6, 9 or 12 months and at the time clinically indicated)</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>coronary stents</intervention_name>
    <description>e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who visited our tertiary hostpital (Severance Cardiovascular Hospital) for
        coronary angiography (with coronary stents or planning for coronary stents)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with coronary stents

          2. Patients who will have coronary stents because of coronary artery stenosis

        Exclusion Criteria:

          1. Hemodynamically unstable patients

          2. Ostial lesions that begin within 15 mm of the left main coronary artery

          3. Lesions with diameter more than 4 mm

          4. Patients with allergy to antiplatelet agent (asprin or clopidogrel)

          5. Patients with hepatic dysfunction (Liver enzyme 3 times the upper limit of normal)

          6. Pregnant and lactating patients

          7. Patients with life expectancy less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myeong ki Hong, MD, PhD</last_name>
    <phone>082 2 2228 8458</phone>
    <phone_ext>88458</phone_ext>
    <email>mkhong61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seodaemun-gu, Shinchondong</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myeong ki Hong, MD, PhD</last_name>
      <phone>82-2-2228-8458</phone>
      <phone_ext>88458</phone_ext>
      <email>mkhong61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT</keyword>
  <keyword>Coronary</keyword>
  <keyword>Stenting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

